ZA981155B - Phthalazines - Google Patents

Phthalazines

Info

Publication number
ZA981155B
ZA981155B ZA981155A ZA981155A ZA981155B ZA 981155 B ZA981155 B ZA 981155B ZA 981155 A ZA981155 A ZA 981155A ZA 981155 A ZA981155 A ZA 981155A ZA 981155 B ZA981155 B ZA 981155B
Authority
ZA
South Africa
Prior art keywords
phthalazines
Prior art date
Application number
ZA981155A
Other languages
English (en)
Inventor
Guido Bold
Joerg Frei
Peter Traxler
Karl-Heinz Altmann
Helmut Mett
David Raymond Stover
Jeanette Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA981155B publication Critical patent/ZA981155B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
ZA981155A 1997-02-13 1998-02-12 Phthalazines ZA981155B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH31597 1997-02-13

Publications (1)

Publication Number Publication Date
ZA981155B true ZA981155B (en) 1998-08-13

Family

ID=4184213

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA981155A ZA981155B (en) 1997-02-13 1998-02-12 Phthalazines

Country Status (32)

Country Link
US (3) US6258812B1 (enExample)
EP (1) EP0970070B1 (enExample)
JP (1) JP3544675B2 (enExample)
KR (1) KR100441362B1 (enExample)
CN (1) CN1251097B (enExample)
AR (1) AR011135A1 (enExample)
AT (1) ATE278686T1 (enExample)
AU (1) AU731852B2 (enExample)
BR (1) BR9807685B1 (enExample)
CA (1) CA2281721C (enExample)
CO (1) CO4950519A1 (enExample)
CY (1) CY2550B1 (enExample)
CZ (1) CZ297534B6 (enExample)
DE (1) DE69826841T2 (enExample)
DK (1) DK0970070T3 (enExample)
ES (1) ES2234097T3 (enExample)
HU (1) HU227972B1 (enExample)
ID (1) ID23698A (enExample)
IL (1) IL131273A0 (enExample)
MY (1) MY128645A (enExample)
NO (1) NO317367B1 (enExample)
NZ (1) NZ337064A (enExample)
PE (1) PE52499A1 (enExample)
PL (1) PL197371B1 (enExample)
PT (1) PT970070E (enExample)
RU (1) RU2207132C2 (enExample)
SI (1) SI0970070T1 (enExample)
SK (1) SK285757B6 (enExample)
TR (1) TR199901953T2 (enExample)
TW (1) TWI250151B (enExample)
WO (1) WO1998035958A1 (enExample)
ZA (1) ZA981155B (enExample)

Families Citing this family (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0929526B1 (en) 1996-09-25 2005-07-27 AstraZeneca AB Qinoline derivatives inhibiting the effect of growth factors such as vegf
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE368665T1 (de) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
ES2291041T3 (es) * 1998-08-13 2008-02-16 Novartis Ag Metodo para tratar enfermedades neovasculares oculares.
WO2000059509A1 (en) * 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
CO5200835A1 (es) 1999-09-28 2002-09-27 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
ES2306306T3 (es) 1999-11-05 2008-11-01 Astrazeneca Ab Nuevos derivados de quinazolina.
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
EP1254138B1 (en) * 2000-02-09 2005-05-11 Novartis AG Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
ATE334973T1 (de) 2000-04-07 2006-08-15 Astrazeneca Ab Chinazolinverbindungen
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
EP1166799A1 (en) * 2000-06-28 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
EP1166798A1 (en) * 2000-06-23 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
MEP13708A (en) * 2000-06-23 2010-06-10 Bayer Schering Pharma Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
EP1311500A2 (en) * 2000-08-09 2003-05-21 AstraZeneca AB Indole, azaindole and indazole derivatives having vegf inhibiting activity
US6903101B1 (en) 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
MXPA03003218A (es) * 2000-10-30 2004-12-03 Kudos Pharm Ltd Derivados de ftalazinona.
EP1810715A3 (en) * 2000-11-22 2009-12-16 Novartis AG Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
US7814641B2 (en) 2001-01-09 2010-10-19 Black & Decker Inc. Method of forming a power tool
US7096566B2 (en) 2001-01-09 2006-08-29 Black & Decker Inc. Method for making an encapsulated coil structure
CZ303611B6 (cs) 2001-02-19 2013-01-09 Novartis Ag Farmaceutické prostredky s obsahem derivátu rapamycinu pro lécení solidních nádoru
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
PT1392313E (pt) 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20030073692A1 (en) * 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
RU2320344C2 (ru) * 2001-09-12 2008-03-27 Новартис Аг Применение 4-пиридилметилфталазинов для лечения рака
CN1330308C (zh) * 2001-09-12 2007-08-08 诺瓦提斯公司 含有4－吡啶基甲基酞嗪的联合产品及其应用
EP1712234B1 (en) * 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
EP1432422A2 (en) * 2001-09-27 2004-06-30 Novartis AG Use of c-kit inhibitors for the treatment of myeloma
BR0213486A (pt) * 2001-10-25 2005-05-10 Novartis Ag Combinações que compreendem um inibidor seletivo de ciclooxigenase-2
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
BR0215360A (pt) * 2001-12-27 2004-12-14 Theravance Inc Derivados de indolina úteis como inibidores de proteìna quinase
US20030171375A1 (en) * 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003233198A1 (en) * 2002-04-30 2003-11-17 Novartis Ag Method for decreasing capillary permeability in the retina
ATE412408T1 (de) * 2002-05-16 2008-11-15 Novartis Pharma Gmbh Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
WO2004002485A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor
US7195876B2 (en) * 2002-08-09 2007-03-27 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
BR0314647A (pt) * 2002-09-24 2005-08-02 Novartis Ag Uso de derivados de 4-piridilmetil-ftalazina para a preparação de um medicamento para o tratamento de sìndromes melodisplásicas
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
US20060148810A1 (en) * 2002-10-10 2006-07-06 Frank Giles Treatment of amm
US7268137B2 (en) 2002-11-07 2007-09-11 Campochiaro Peter A Ocular therapy
EP1562591A1 (en) * 2002-11-12 2005-08-17 Novartis AG Treatment of mesothelioma
US7094785B1 (en) 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
JP2006512360A (ja) * 2002-12-20 2006-04-13 ダナ−ファーバー　キャンサー　インスティテュート，インコーポレイテッド ＶｏｎＨｉｐｐｅｌ−Ｌｉｎｄａｕ病の処置
WO2004058234A2 (en) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
PL1602647T3 (pl) 2003-03-07 2014-05-30 Santen Pharmaceutical Co Ltd Nowy związek zawierający jako podstawnik grupę 4-pirydyloalkilotio
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20040242886A1 (en) * 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
ES2467160T3 (es) 2003-05-19 2014-06-12 Irm Llc Compuestos y composiciones inmunosupresores
AU2004265595B2 (en) 2003-07-18 2011-12-08 Amgen Fremont Inc. Specific binding agents to hepatocyte growth factor
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
ATE428426T1 (de) 2003-11-18 2009-05-15 Novartis Pharma Gmbh Hemmer der mutanten form von kit
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
EP1717229B1 (en) 2004-02-17 2011-06-15 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
FR2868780B1 (fr) * 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
EP1827434B1 (en) 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
ES2351613T3 (es) 2005-03-03 2011-02-08 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que tiene un grupo quinolilalquiltio.
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
ES2548729T3 (es) 2005-03-31 2015-10-20 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio
WO2006113172A1 (en) * 2005-04-13 2006-10-26 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of gastrointestinal, genitourinary, lymphoid and pulmonary cancers
MX2007013741A (es) 2005-05-02 2008-01-21 Novartis Ag Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistemica.
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1731153A1 (en) * 2005-06-07 2006-12-13 Schering Aktiengesellschaft Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)¬4-(4-pyridylmethyl)phthalazin-1-yl| and salts thereof
EP1731154A1 (en) 2005-06-07 2006-12-13 Schering Aktiengesellschaft Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
GB0517205D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
US20080255149A1 (en) 2005-09-27 2008-10-16 Novartis Ag Carboxyamine Compounds and Methods of Use Thereof
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP2022498A3 (en) 2005-11-21 2012-08-15 Novartis AG Neuroendocrine tumour treatment
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JP2009526050A (ja) 2006-02-10 2009-07-16 アムジエン・インコーポレーテツド Ａｍｇ７０６の水和物形態
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
AU2007240548A1 (en) 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US8777120B2 (en) * 2006-04-15 2014-07-15 International Business Machines Corporation Hydronic radiant flooring heating system
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2021338A1 (en) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
MX2008014292A (es) 2006-05-09 2008-11-18 Novartis Ag Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
TW200817409A (en) 2006-08-04 2008-04-16 Takeda Pharmaceutical Fused heterocyclic derivative and use thereof
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2125781A2 (en) 2006-12-20 2009-12-02 Amgen Inc. Substituted heterocycles and methods of use
AU2008205252B2 (en) 2007-01-09 2013-02-21 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
CA2676163A1 (en) 2007-01-29 2008-08-07 Santen Pharmaceutical Co., Ltd. Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
JP2010519204A (ja) 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用
PE20090370A1 (es) 2007-06-05 2009-04-30 Takeda Pharmaceutical Derivados de heterociclo fusionado como inhibidores de quinasa
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
HUE037265T2 (hu) 2007-08-21 2018-08-28 Amgen Inc Humán c-fms antigént kötõ proteinek
WO2009025358A1 (ja) 2007-08-23 2009-02-26 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
CN101116664B (zh) * 2007-08-28 2010-05-19 山东省科学院生物研究所 化合物1-(4-氯苯胺基)-4-(4-甲基吡啶基)-2,3-二氮杂萘的应用
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
AR069798A1 (es) 2007-12-20 2010-02-17 Novartis Ag Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa.
CA2719477C (en) 2008-03-26 2016-11-08 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101791403B1 (ko) 2008-08-15 2017-10-30 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 퓨린 유도체
ES2704986T3 (es) 2008-10-16 2019-03-21 Celator Pharmaceuticals Inc Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
EP2399921B1 (en) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
MX2011006622A (es) 2008-12-18 2011-07-12 Novartis Ag Sales novedosas.
HRP20131106T1 (hr) 2008-12-18 2013-12-20 Novartis Ag Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
BRPI0922457A2 (pt) 2008-12-18 2015-12-15 Novartis Ag forma polimórfica de ácido 1-(4-{1-[(e)-4-ciclo-hexil-3-trifluormetil-benziloxi-imino]-etil)-2-etil-benzil)-azetidino-3-carboxílico"
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
AU2010264698C1 (en) 2009-06-26 2013-05-16 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
US8497368B2 (en) 2009-08-12 2013-07-30 Novartis Ag Heterocyclic hydrazone compounds
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
HUE026957T2 (en) 2009-08-19 2016-07-28 Eisai R&D Man Co Ltd A pharmaceutical composition comprising a quinoline derivative
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
CA2771936A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
JP2013504543A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 二環ヘテロアリール類のエーテル誘導体
WO2011039367A2 (en) 2009-10-02 2011-04-07 Boehringer Ingelheim International Gmbh Therapeutic uses of pharmaceutical compositions
NZ599565A (en) 2009-11-04 2013-05-31 Novartis Ag Heterocyclic sulfonamide derivatives useful as mek inhibitors
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
BR112012013735A2 (pt) 2009-12-08 2019-09-24 Novartis Ag derivados heterocícilicos de sulfonamida
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
US20130085161A1 (en) 2010-06-17 2013-04-04 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
US20130090342A1 (en) 2010-06-17 2013-04-11 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CN103097418A (zh) 2010-07-09 2013-05-08 霍夫曼-拉罗奇有限公司 抗神经毡蛋白抗体及使用方法
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012068487A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
EP2640385A1 (en) 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment based on hypoxic status
PE20140293A1 (es) 2011-01-31 2014-03-19 Novartis Ag Novedosos derivados heterociclicos
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
US20130338152A1 (en) 2011-03-08 2013-12-19 Irm Llc Fluorophenyl bicyclic heteroaryl compounds
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CA2838029A1 (en) 2011-06-09 2012-12-13 Novartis Ag Heterocyclic sulfonamide derivatives
JP5941142B2 (ja) 2011-06-16 2016-06-29 コーリア リサーチ インスティテュート オブ ケミカル テクノロジー １，３−ジオキソインデン誘導体、その薬学的に許容される塩又は光学異性体、その調製方法及びそれを抗ウイルス活性成分として含有する医薬組成物
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
DK3517539T3 (en) 2011-07-15 2023-01-16 Boehringer Ingelheim Int Farmaceutiske sammensætninger til behandling af type i og type ii diabetes
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
EP2758043A4 (en) 2011-08-17 2016-02-24 Dennis M Brown COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY APPLIED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
ES2587533T3 (es) 2011-10-28 2016-10-25 Novartis Ag Derivados de purina y su uso en el tratamiento de enfermedades
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
EP2794591A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
CN104125955A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
AU2012355624A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
WO2013096051A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
JP2015503517A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CA2868202C (en) 2012-04-03 2021-08-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
KR20150034209A (ko) 2012-06-26 2015-04-02 델 마 파마슈티컬스 인코포레이티드 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
PL3882244T3 (pl) 2012-12-14 2025-06-16 Korea Research Institute Of Chemical Technology ZWIĄZEK, JEGO FARMACEUTYCZNIE DOPUSZCZALNA SÓL LUB IZOMER OPTYCZNY, SPOSÓB ICH WYTWARZANIA i ZAWIERAJĄCA JE, JAKO SKŁADNIK AKTYWNY, KOMPOZYCJA FARMACEUTYCZNA DO PROFILAKTYKI LUB LECZENIA CHORÓB WIRUSOWYCH
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
AU2014230096C1 (en) 2013-03-15 2019-08-29 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
EP4000619A1 (en) 2013-12-06 2022-05-25 Novartis AG Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
EP3174869B1 (en) 2014-07-31 2020-08-19 Novartis AG Combination therapy of a met inhibitor and an egfr inhibitor
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
AU2016205311B2 (en) 2015-01-08 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
WO2016123796A1 (en) * 2015-02-06 2016-08-11 Abbvie Inc. Substituted phthalazines
KR102763349B1 (ko) 2015-02-25 2025-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
BR112017018908A2 (pt) 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
RU2729936C2 (ru) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
US20180280370A1 (en) 2015-11-02 2018-10-04 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
UA124474C2 (uk) 2016-12-22 2021-09-22 Емджен Інк. БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
SG11201910100PA (en) 2017-05-16 2019-11-28 Eisai R&D Man Co Ltd Treatment of hepatocellular carcinoma
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN116003405A (zh) 2017-09-08 2023-04-25 美国安进公司 Kras g12c的抑制剂及其使用方法
EP3697425A1 (en) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
MX2020011907A (es) 2018-05-10 2021-01-29 Amgen Inc Inhibidores de kras g12c para el tratamiento de cancer.
MA52765A (fr) 2018-06-01 2021-04-14 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
EP3807276B1 (en) 2018-06-12 2025-12-10 Amgen Inc. Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
CA3103735A1 (en) 2018-07-17 2020-01-23 Boehringer Ingelheim International Gmbh Cardio- and renosafe antidiabetic therapy
US20210299129A1 (en) 2018-07-17 2021-09-30 Boehringer Ingelheim International Gmbh Cardiosafe Antidiabetic Therapy
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3898592B1 (en) 2018-12-20 2024-10-09 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
ES2953821T3 (es) 2018-12-20 2023-11-16 Amgen Inc Inhibidores de KIF18A
CN113226473B (zh) 2018-12-20 2025-05-13 美国安进公司 Kif18a抑制剂
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MX2021010319A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
CN114173774A (zh) * 2019-05-14 2022-03-11 斯克里普斯研究院 用于治疗神经退行性和代谢性疾患的化合物
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
KR20220011670A (ko) 2019-05-21 2022-01-28 암젠 인크 고체 상태 형태
MX2022001296A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
MX2022001181A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
CN114302880B (zh) 2019-08-02 2025-07-15 美国安进公司 Kif18a抑制剂
CA3155857A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
EP4054719A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
CN114901662A (zh) 2019-11-08 2022-08-12 锐新医药公司 双环杂芳基化合物及其用途
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides
KR20220101125A (ko) 2019-11-14 2022-07-19 암젠 인크 Kras g12c 억제제 화합물의 개선된 합성
JP2023501522A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改良合成法
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
TW202140011A (zh) 2020-01-07 2021-11-01 美商銳新醫藥公司 Shp2抑制劑給藥和治療癌症的方法
US12083092B2 (en) 2020-04-20 2024-09-10 Novartis Ag Antiviral 1,3-di-oxo-indene compounds
JP7592748B2 (ja) 2020-04-20 2024-12-02 ノバルティス アーゲー 抗ウイルス１，３－ジ－オキソ－インデン化合物
BR112022025550A2 (pt) 2020-06-18 2023-03-07 Revolution Medicines Inc Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
JP2023541236A (ja) 2020-09-03 2023-09-29 レボリューション メディシンズ インコーポレイテッド Ｓｈｐ２変異を有する悪性腫瘍を治療するためのｓｏｓ１阻害剤の使用
CN117683049A (zh) 2020-09-15 2024-03-12 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
AR124449A1 (es) 2020-12-22 2023-03-29 Qilu Regor Therapeutics Inc Inhibidores de sos1 y usos de los mismos
US20240174651A1 (en) * 2021-01-28 2024-05-30 The Scripps Research Institute Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
JP2024517845A (ja) 2021-05-05 2024-04-23 レボリューション メディシンズ インコーポレイテッド がん治療のためのｒａｓ阻害剤
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
US20250059182A1 (en) * 2021-06-21 2025-02-20 Mirati Therapeutics, Inc. Sos1 inhibitors
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20250282782A1 (en) 2021-12-17 2025-09-11 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
KR20230098078A (ko) * 2021-12-24 2023-07-03 제일약품주식회사 신규한 바이사이클릭 헤테로사이클릴 화합물 및 이의 용도
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
KR20240156373A (ko) 2022-03-07 2024-10-29 암젠 인크 4-메틸-2-프로판-2-일-피리딘-3-카르보니트릴의 제조 방법
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
IL320217A (en) 2022-10-14 2025-06-01 Black Diamond Therapeutics Inc Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
AU2024243852A1 (en) 2023-04-07 2025-11-06 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202446388A (zh) 2023-04-14 2024-12-01 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (enExample) 1957-05-07
US2960504A (en) 1957-05-07 1960-11-15 Ciba Pharm Prod Inc 1-hydrazino, 4-pyridyl methyl-phthalazines
GB1094044A (en) 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
DE1695994A1 (de) 1967-05-05 1971-05-19 Vantorex Ltd Verfahren zur Herstellung von Phthalazinen
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
CN1058390C (zh) * 1993-10-15 2000-11-15 伊莱利利公司 苯并噻吩类化合物的用途
ATE267174T1 (de) * 1994-08-09 2004-06-15 Eisai Co Ltd Kondensierte pyridazinverbindungen
EP0876366B1 (en) * 1996-01-15 2001-07-25 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
DE19617863A1 (de) 1996-04-23 1997-10-30 Schering Ag Phthalazinderivate, deren Herstellung und Verwendung als Arzneimittel
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ITMI981670A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
ES2291041T3 (es) * 1998-08-13 2008-02-16 Novartis Ag Metodo para tratar enfermedades neovasculares oculares.

Also Published As

Publication number Publication date
TR199901953T2 (xx) 1999-10-21
US20020091261A1 (en) 2002-07-11
CZ285399A3 (cs) 1999-11-17
NO993888L (no) 1999-10-11
US6710047B2 (en) 2004-03-23
RU2207132C2 (ru) 2003-06-27
IL131273A0 (en) 2001-01-28
CZ297534B6 (cs) 2007-01-03
US6514974B2 (en) 2003-02-04
EP0970070A1 (en) 2000-01-12
ES2234097T3 (es) 2005-06-16
AU731852B2 (en) 2001-04-05
JP2001508800A (ja) 2001-07-03
DE69826841T2 (de) 2006-02-09
JP3544675B2 (ja) 2004-07-21
TWI250151B (en) 2006-03-01
US20030191129A1 (en) 2003-10-09
CN1251097B (zh) 2011-10-19
WO1998035958A1 (en) 1998-08-20
SK285757B6 (sk) 2007-07-06
NZ337064A (en) 2001-04-27
MY128645A (en) 2007-02-28
NO317367B1 (no) 2004-10-18
PT970070E (pt) 2005-02-28
DE69826841D1 (de) 2004-11-11
SK109699A3 (en) 2000-03-13
HUP0001046A2 (hu) 2001-04-28
DK0970070T3 (da) 2005-02-14
KR20000071049A (ko) 2000-11-25
HUP0001046A3 (en) 2002-04-29
CY2550B1 (enExample) 2008-07-02
KR100441362B1 (ko) 2004-07-23
NO993888D0 (no) 1999-08-12
ID23698A (id) 2000-05-11
ATE278686T1 (de) 2004-10-15
AU6621898A (en) 1998-09-08
BR9807685A (pt) 2000-03-21
HU227972B1 (en) 2012-07-30
AR011135A1 (es) 2000-08-02
CA2281721C (en) 2008-01-22
SI0970070T1 (en) 2005-04-30
CO4950519A1 (es) 2000-09-01
EP0970070B1 (en) 2004-10-06
CA2281721A1 (en) 1998-08-20
BR9807685B1 (pt) 2013-05-21
CN1251097A (zh) 2000-04-19
PL197371B1 (pl) 2008-03-31
PL335113A1 (en) 2000-04-10
US6258812B1 (en) 2001-07-10
PE52499A1 (es) 1999-06-10

Similar Documents

Publication Publication Date Title
ZA981155B (en) Phthalazines
DE59803915D1 (en) Bandwaage
DE59806556D1 (en) Fmcw-sensor
DE59805100D1 (en) Containerbrücke
DE59803341D1 (en) Handhobelmaschine
DE59808840D1 (en) Compoundpumpe
DE69727985D1 (en) Extravasationserkennungsvorrichtung
DE59811907D1 (en) Transponder-system
DE59803148D1 (en) Dimensionsstabile thermoplastische formmassen
DE69801658D1 (en) Polyurethanhartschaumstoffe
DE69804606D1 (en) Cyclohexandiolderivate
DE69729893D1 (en) Druckbläter
DE59708342D1 (en) Basophilen-degranulationstest
DE69715258D1 (en) Präzisionshydraulikfutter
DE59806884D1 (en) Dexamethason-gel
DE69737400D1 (en) Substituierte naphthopyrane
DE59811113D1 (en) Laryngoskop
DE69735266D1 (en) Substituierte naphthopyrane
CA79884S (en) Moniitor
CA82333S (en) Remorque
DE59809032D1 (en) Telephonsystem
CA82218S (en) Sports-glasses
CA80915S (en) Elbow-rest
CA80910S (en) Aeroglisseur
CA82745S (en) Handleset